Nasdaq

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...
Business Insider

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...
MarketWatch

Eli Lilly's Emgality gets FDA approval for episodic cluster headaches

Eli Lilly & Co. said Wednesday Emgality injection was approved by the U.S. Food and Drug Administration for the treatment of episodic cluster headache in adults. Lilly said Emgality is the first and ...
FiercePharma

Lilly’s Emgality nabs third-to-market migraine nod but aims to be 'treatment of choice' in CGRP

Eli Lilly may not be first to the market with its next-gen migraine drug Emgality, but with an approval Thursday, the drugmaker still believes it can be the “treatment of choice” for migraine ...
FiercePharma

NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...
Healio

FDA approves Emgality for migraine prevention

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Emgality, a once-monthly, self-administered, subcutaneous injection, for the preventive ...
Monthly Prescribing Reference

Migraine Prevention Treatment Emgality Gets FDA Approval

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine. The Food and Drug ...
KRQE Blogs

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...
AOL

Lilly's Emgality Gets FDA Approval for Cluster Headache

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.
Healio

FDA grants headache drug priority review

Please provide your email address to receive an email when new articles are posted on . The FDA recently granted priority review to the supplemental Biologics License Application for Emgality ...
Nasdaq

Lilly's Emgality Gets FDA Priority Review for Cluster Headache

Eli Lilly and CompanyLLY announced that the FDA has granted a priority review to the supplemental biologics license application (sBLA) for its calcitonin gene-related peptide (CGRP) antibody, Emgality ...